Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review.

Author: AimanWajeeha, AliMuhammad Ashar, AliRimsha, AnwarAqsa, AnwarMuhammad Yasir, BajwaShammas Farooq, MirzaNayab, RehmanSana, SaeedMemoona, ShahSyed S

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Selpercatinib and pralsetinib are the only FDA-approved RET-specific tyrosine kinase inhibitors for RET-altered tumors. This review summarizes the efficacy and safety of these drugs based on a comprehensive literature search. Objective response rates were 60-89%, and ≥Grade 3 adverse events were reported in 28-53% of patients.
Paper Details　
Original Abstract of the Article :
RET proto-oncogene encodes receptor tyrosine kinase. Selpercatinib and pralsetinib are the only RET-specific tyrosine kinase inhibitors approved by FDA in RET-altered tumors. We searched PubMed, Embase, Cochrane, WOS, and Clinicaltrials.gov. Objective-response, complete-response, and partial-respons...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/07357907.2023.2255655

データ提供：米国国立医学図書館（NLM）

RET-Specific Kinase Inhibitors: Effective Treatment for RET-Altered Cancers

RET proto-oncogene plays a crucial role in the development of certain cancers. Selpercatinib and pralsetinib are two RET-specific tyrosine kinase inhibitors recently approved by the FDA for treating RET-altered tumors. This study systematically reviews the efficacy and safety of these targeted therapies in patients with RET-altered cancers.

RET-Specific Inhibitors: A Targeted Approach to Treating RET-Altered Cancers

The review found that selpercatinib and pralsetinib are effective in treating RET-altered tumors, with impressive objective response rates. While side effects are common, they are generally manageable, and the inhibitors are well-tolerated by most patients. This study provides valuable insights into the potential of targeted therapies in fighting cancer, offering hope for patients with RET-altered cancers.

Precision Medicine: Targeting Cancer with RET-Specific Inhibitors

This study exemplifies the growing field of precision medicine, where treatments are tailored to the specific genetic and molecular characteristics of a patient's cancer. The effectiveness of RET-specific inhibitors underscores the importance of identifying and targeting the underlying causes of cancer. This study encourages continued research to develop new and more effective targeted therapies for a wide range of cancers.

Dr. Camel's Conclusion

This review provides a glimpse into the future of cancer treatment, with a focus on targeted therapies. Just as a camel navigates the desert landscape, oncologists are seeking new ways to navigate the complexities of cancer, using precision medicine to develop more effective and personalized treatments.

Date :
  1. Date Completed 2023-11-01
  2. Date Revised 2023-11-01
Further Info :

Pubmed ID

37782113

DOI: Digital Object Identifier

10.1080/07357907.2023.2255655

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.